Emergent BioSolutions’ smallpox vaccine, ACAM2000, now has an additional FDA approval covering mpox. It’s one of two FDA-approved mpox vaccines, joining Jynneos from Bavarian Nordic.
The enduring legacy of the Ebola crisis serves as a poignant reminder of our shared responsibility in safeguarding public health and preventing future pandemics.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.
Bavarian Nordic will concentrate on its portfolio and pipeline of infectious diseases vaccines, including top seller Jynneos, approved for mpox and smallpox. The company only had one clinical-stage cancer vaccine program.
The Coalition for Epidemic Preparedness Innovations, or CEPI, has pledged up to $90 million to BioNTech’s messenger RNA vaccine candidates for mpox. This research could help advance the scientific understanding of the application of mRNA technology to Orthopoxviruses, which includes mpox, formerly known as monkeypox.